Home › Research › Biomarkers
Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic
Piura YD, Figdore DJ, Lachner C, Bornhorst J, Algeciras-Schimnich A, Graff-Radford NR, Day GS. Alzheimer's & Dementia, 2025-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Plasma biomarkers of Alzheimer's disease (AD) represent accessible alternatives to positron emission tomography (PET) and cerebrospinal fluid (CSF)-based biomarkers in well-characterized cohorts. It remains to be determined whether performance is maintained in outpatient clinics comprised of patients with multiple causes of cognitive impairment. Methods Plasma phosphorylated tau217 (p-tau217) and amyloid beta (Aβ) 42/40 were measured in 509 patients evaluated in a tertiary-care memory clinic. Biomarker performance was compared across diagnoses, referencing established cutpoints for positive and negative biomarkers. Results Plasma p-tau217 distinguished patients with diagnoses of symptomatic AD with 95% sensitivity and 82% specificity. Integration of Aβ42 measurements (p-tau217/Aβ42) incrementally improved specificity (86%). Plasma p-tau217 and p-tau217/Aβ42 concentrations closely associated with established CSF biomarkers of AD (area under the curve [AUC]: 0.94 and 0.96, respectively). Reduced kidney function associated with elevated plasma p-tau217 and p-tau217/Aβ42 concentrations in patients without AD (referencing CSF biomarkers). Discussion Plasma p-tau217 and p-tau217/Aβ42 concentrations demonstrated robust diagnostic performance in a heterogeneous clinical cohort; interpretation requires consideration of kidney function. Highlights Plasma phosphorylated tau217 (p-tau217) reliably identified clinic patients with Alzheimer's disease. A two-cutpoint strategy yielded definitive results in 86% of patients. Integration of plasma amyloid beta (Aβ; p-tau217/Aβ42) minimally improved diagnostic performance. Plasma p-tau217 levels were increased in patients with kidney dysfunction.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 509 participants. In 509 patients at a tertiary-care memory clinic, plasma p-tau217 distinguished symptomatic Alzheimer's disease with 95% sensitivity and 82% specificity, and adding Aβ42 improved specificity to 86%. Reported effect size: Sensitivity 95%, specificity 82% (86% with Aβ42 ratio) for symptomatic AD.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Piura, Y. D., Figdore, D. J., Lachner, C., Bornhorst, J., Algeciras-Schimnich, A., Graff-Radford, N. R., et al. (2025). Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70316
Vancouver
Piura YD, Figdore DJ, Lachner C, Bornhorst J, Algeciras-Schimnich A, Graff-Radford NR, et al. Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70316. PMID: 40476540.
BibTeX
@article{piura2025-40476540,
author = {Piura, Y. D. and Figdore, D. J. and Lachner, C. and Bornhorst, J. and Algeciras-Schimnich, A. and Graff-Radford, N. R. and Day, G. S.},
title = {{Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic}},
journal = {Alzheimer's \& Dementia},
year = {2025},
doi = {10.1002/alz.70316},
pmid = {40476540},
url = {https://doi.org/10.1002/alz.70316}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Plasma p-tau217 distinguished patients with diagnoses of symptomatic AD with 95% sensitivity and 82% specificity.
- Plasma p-tau217 and p-tau217/Aβ42 concentrations closely associated with established CSF biomarkers of AD (area under the curve [AUC]: 0.94 and 0.96, respectively).
- Reduced kidney function associated with elevated plasma p-tau217 and p-tau217/Aβ42 concentrations in patients without AD (referencing CSF biomarkers).
- Discussion Plasma p-tau217 and p-tau217/Aβ42 concentrations demonstrated robust diagnostic performance in a heterogeneous clinical cohort; interpretation requires consideration of kidney function.
- A two-cutpoint strategy yielded definitive results in 86% of patients.
Why it matters
In 509 patients at a tertiary-care memory clinic, plasma p-tau217 distinguished symptomatic Alzheimer's disease with 95% sensitivity and 82% specificity, and adding Aβ42 improved specificity to 86%. The study also found that reduced kidney function was associated with elevated plasma p-tau217 and p-tau217/Aβ42 concentrations in patients without Alzheimer's disease, so interpretation requires consideration of kidney function.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants509
- Effect sizeSensitivity 95%, specificity 82% (86% with Aβ42 ratio) for symptomatic AD
- Evidence strengthModerate
Limitations
Most patients were non-Hispanic White, so evaluation in representative cohorts with more Black and Hispanic patients is needed; the academic referral centre's expertise in normal-pressure hydrocephalus likely over-represented that diagnosis compared with community practice.
How this study scored 62/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 61 of the 98 points we could judge it on, which is 62 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 509 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 30 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 19.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Gregory Scott Day: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40476540) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 61 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 61 of the 98 points we could judge it on is 62 out of 100. |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.